Ultragenyx Competitors and Similar CompaniesClear all
Ultragenyx's competitors and similar companies include Horizon Therapeutics, Ionis Pharmaceuticals, IntraBio and GeneQuine Biotherapeutics.
 Horizon Therapeutics Horizon Therapeutics (formerly known as Horizon Pharma) is a biopharmaceutical company focused on researching, developing, and commercializing medicines. |  Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  IntraBio IntraBio is a biopharmaceutical company that develops therapies for genetic and neurodegenerative diseases. |  GeneQuine Biotherapeutics GeneQuine Biotherapeutics is a company developing gene therapy for the treatment of osteoarthritis. | ||
Founding Date | Founding Date 2010 | Founding Date 2008 | Founding Date 1989 | Founding Date 2015 | Founding Date 2012 |
Type | Type Public | Type Subsidiary | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Dublin, IE HQ | Locations Begbroke, GB HQ | Locations Hamburg, DE HQ | ||
Employees | Employees 1,2763% decrease | Employees 2,662 | Employees 1,40231% increase | Employees 4 | Employees 195% decrease |
Valuation ($) | Valuation ($) 4.9 b | Valuation ($) N/A | Valuation ($) 6.3 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $673m (FY, 2025) | Revenue (est.) $3.6b (FY, 2022) | Revenue (est.) $943.7m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $920.2m (FY, 2022) | Cost of goods $15.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $2.7b (FY, 2022) | Gross profit $927.8m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($575m) (FY, 2025) | Net income $521.5m (FY, 2022) | Net income ($381.4m) (FY, 2025) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 3 (Sep, 2021) | Phase I Trials Products 1 (FY, 2023) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 12 (Sep, 2021) | Phase II Trials Products 18 (FY, 2024) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 2 (Sep, 2021) | Phase III Trials Products 17 (FY, 2024) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 4.9m (almost 8 years ago) | Latest funding round $ 11m (over 5 years ago) |
Total funding raised | Total funding raised $ 200.1m | Total funding raised $ 63m | Total funding raised N/A | Total funding raised $ 4.9m | Total funding raised $ 11m |
For sources of this data, please see the company profile
View Company Profiles
Horizon Therapeutics
HQ
Dublin, IE
Horizon Therapeutics (formerly known as Horizon Pharma) is a biopharmaceutical company focused on researching, developing, and commercializing medicines.
View companyIonis Pharmaceuticals
HQ
Carlsbad, US
Employees
1,402↑ 31% increase
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View companyIntraBio
HQ
Begbroke, GB
Employees
4
IntraBio is a biopharmaceutical company that develops therapies for genetic and neurodegenerative diseases.
View companyGeneQuine Biotherapeutics
HQ
Hamburg, DE
Employees
19↓ 5% decrease
GeneQuine Biotherapeutics is a company developing gene therapy for the treatment of osteoarthritis.
View company